No matches

Pulmonology

ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.

MD, MPH

Mario Castro +2 more

52 minutes

Related resources

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

4 min

videoanimation

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

45 min

videoanimation

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

3 min

Infographic

Compounded Burden of Co-existing Type 2 Airway Diseases

4 min

expert video

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

4 min

expert video

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

3 min

expert video

The Burden in Patients with CRSwNP and Coexisting Asthma

8 min

expert video

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

5 min

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

interactivity

Learning objectives

Highlight the burden of mucus plugging in asthma and its correlation with lung function decline
Educate on the role of type 2 inflammation in the development of mucus plugs
Explore the available clinical data supporting the impact on mucus plugging and the disease-modifying potential of the current therapeutic landscape

About these experts

Pulmonology

MD, MPH

Mario Castro

Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research, University of Kansas School of Medicine

Pulmonology

MD, MSc

Simon Couillard

Professor Couillard is a respirologist and the Québec Lung Association Chair of Respiratory Research at the Université de Sherbrooke, Canada. He leads a team investigating ways to use biomarkers to predict and prevent asthma attacks and improve asthma management.

Pulmonology

Njira Lugogo

Dr. Lugogo is a Professor of Medicine in the Division of Pulmonary, Critical Care Medicine and is the Director of the Michigan Medicine Asthma Program. She is also the Program Director of INHALE, a statewide collaborative quality improvement program that focuses on improving the care of patients with asthma and COPD in Michigan.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region

ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

Related resources

Type 2 Inflammation Underpins Pediatric Severe Asthma

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

FeNO as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

On-Treatment Clinical Remission in Asthma Patients Case Tool

What Differentiates COPD Exacerbations From Asthma Exacerbations?

Clinical Manifestations Associated With Airway Remodeling in Asthma

Impact of Exacerbations in COPD

Exacerbations Lead to Worsening Lung Function

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Mucus Plugging as a Potential Target in Asthma Management

Multifaceted Role of IL-13 in Airway Remodeling

Pediatric Asthma Trajectory and Clinical Remission

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

Compounded Burden of Co-existing Type 2 Airway Diseases

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

The Cycle of Inflammation in Adult Asthma

Learning objectives

About these experts

Mario Castro

Simon Couillard

Njira Lugogo

ADVENT On Air | The Road Ahead: Achieving Remission for Patients With Asthma